VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment

被引：90

作者：

Nagengast, Wouter B. ^{[2
]}

Lub-de Hooge, Marjolijn N. ^{[3
,4
]}

Oosting, Sjoukje F. ^{[2
]}

den Dunnen, Wilfred F. A. ^{[5
]}

Warnders, Frank-Jan ^{[2
]}

Brouwers, Adrienne H. ^{[4
]}

de Jong, Johan R. ^{[4
]}

Price, Patricia M. ^{[6
]}

Hollema, Harry ^{[5
]}

Hospers, Geke A. P. ^{[2
]}

Elsinga, Philip H. ^{[4
]}

Hesselink, Jan Willem ^{[7
]}

Gietema, Jourik A. ^{[2
]}

de Vries, Elisabeth G. E. ^{[1
,2
]}

机构：

[1] Univ Med Ctr Groningen, Dept Med Oncol, NL-9700 RB Groningen, Netherlands

[2] Univ Groningen, Dept Med Oncol, Groningen, Netherlands

[3] Univ Groningen, Dept Hosp & Clin Pharm, Groningen, Netherlands

[4] Univ Groningen, Dept Nucl Med & Mol Imaging, Groningen, Netherlands

[5] Univ Groningen, Dept Pathol, Groningen, Netherlands

[6] Christie Hosp, Acad Dept Radiat Oncol, Manchester, Lancs, England

[7] Univ Groningen, Dept Surg, Groningen, Netherlands

来源：

CANCER RESEARCH | 2011年 / 71卷 / 01期

关键词：

TYROSINE KINASE INHIBITOR; RENAL-CELL CARCINOMA; RADIOLABELED BEVACIZUMAB; PHASE-II; GROWTH; CANCER; THERAPY; ANGIOGENESIS; METASTASIS; RESISTANCE;

D O I：

10.1158/0008-5472.CAN-10-1088

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Non-invasive imaging of angiogenesis could ease the optimization of antiangiogenesis treatments for cancer. In this study, we evaluated the role of VEGF-PET as a biomarker of dynamic angiogenic changes in tumors following treatment with the kinase inhibitor sunitinib. The effects of sunitinib treatment and withdrawal on the tumor was investigated using the new VEGF-PET tracer Zr-89-ranibizumab as well as F-18-FDG PET, and O-15-water PET in mouse xenograft models of human cancer. The obtained imaging results were compared with tumor growth, VEGF plasma levels and immunohistologic analyzes. In contrast to F-18-FDG and O-15-water PET, VEGF-PET demonstrated dynamic changes during sunitinib treatment within the tumor with a strong decline in signal in the tumor center and only minimal reduction in tumor rim, with a pronounced rebound after sunitinib discontinuation. VEGF-PET results corresponded with tumor growth and immunohistochemical vascular- and tumor-markers. Our findings highlight the strengths of VEGF-PET imaging to allow serial analysis of angiogenic changes in different areas within a tumor. Cancer Res; 71(1); 143-53. (C) 2010 AACR.

引用

页码：143 / 153

页数：11

共 38 条

[1] Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane [J].

Anderson, H ;

Yap, JT ;

Wells, P ;

Miller, MP ;

Propper, D ;

Price, P ;

Harris, AL .

BRITISH JOURNAL OF CANCER, 2003, 89 (02) :262-267

[2]

[Anonymous], CLIN TRIAL REG DAT

[3] Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes [J].

Backer, Marina V. ;

Levashova, Zoya ;

Patel, Vimalkumar ;

Jehning, Brian T. ;

Claffey, Kevin ;

Blankenberg, Francis G. ;

Backer, Joseph M. .

NATURE MEDICINE, 2007, 13 (04) :504-509

[4] Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations [J].

Behr, TM ;

Goldenberg, DM ;

Becker, W .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (02) :201-212

[5] Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane [J].

Burstein, Harold J. ;

Elias, Anthony D. ;

Rugo, Hope S. ;

Cobleigh, Melody A. ;

Wolff, Antonio C. ;

Eisenberg, Peter D. ;

Lehman, Mary ;

Adams, Bonne J. ;

Bello, Carlo L. ;

DePrimo, Samuel E. ;

Baum, Charles M. ;

Miller, Kathy D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1810-1816

[6] Multimodality molecular imaging of tumor angiogenesis [J].

Cai, Weibo ;

Chen, Xiaoyuan .

JOURNAL OF NUCLEAR MEDICINE, 2008, 49 :113S-128S

[7] Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors [J].

Casanovas, O ;

Hicklin, DJ ;

Bergers, G ;

Hanahan, D .

CANCER CELL, 2005, 8 (04) :299-309

[8] A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities [J].

Christensen, J. G. .

ANNALS OF ONCOLOGY, 2007, 18 :3-10

[9]

Desar IM, 2009, ACTA ONCOL, P1

[10]

DEVRIES EGE, 1989, CANCER RES, V49, P4175

← 1 2 3 4 →